AlzeCure Pharma AB (publ) (FN STO: ALZCUR), a pharmaceutical company that develops a broad portfolio of drug candidates for diseases affecting the central nervous system, with projects in both Alzheimer’s disease and pain, today announced that an abstract on its lead drug candidate ACD856 in Alzheimer's disease has been accepted for presentation at AAIC 2021, which this year will be held in Denver, USA, on July 26-30.
The abstract, titled ACD856 – a novel positive allosteric modulator of Trk-signaling in clinical development for the treatment of Alzheimer’s disease, will be presented at the global Alzheimer’s Association International Conference (AAIC) 2021 by Dr. Johan Sandin, CSO at AlzeCure. Other authors include Dr. Pontus Forsell, Head of Discovery, Dr. Gunnar Nordvall, Head of Chemistry and Matthias Rother, Medical Program Director at AlzeCure.
The presentation includes study results demonstrating how ACD856 binds to neurotrophin receptors, so-called Trk receptors, which are considered to underlie the positive effects that the substance has on nerve cell communication and cognitive function in several preclinical models. Furthermore, data from various preclinical cognition and safety studies will be presented, as well as data from the first clinical study performed with ACD856.
“The unique biological mechanism affected by ACD856 has a strong link to cognitive function in humans. By stimulating NGF- and BDNF-signaling, we have shown that we can improve memory function in a number of preclinical models,” said Johan Sandin, CSO at AlzeCure Pharma.
“The exciting results which we now present form the basis for the ongoing clinical phase I study with ACD856. The abstract approval at this prestigious international Alzheimer's conference is a clear validation of our NeuroRestore platform and strengthens our conviction that AlzeCure is at the forefront of research," said Martin Jönsson, CEO of AlzeCure Pharma AB.